Filed, approved, available: why a medicine's date is three different dates

TL;DR

• "Submitted", "filed", "accepted", "approved" and "launched" are five different events, often years apart - only the last one means a person can obtain the medicine.
• A filing is a company's claim, not a regulator's agreement - submissions can be refused at acceptance, attract further questions, or end in a decision that is not an approval.
• An advisory committee recommendation is non-binding and is emphatically not an approval.
• Approval is not a launch: manufacturing at scale, distribution, pricing and - outside the US - a separate national registration all still have to happen.
• CagriSema was submitted in December 2025 and remains under review, not approved, as of 26 October 2026.
• Retatrutide is the live example of "results in hand, nothing filed": its big trials have reported and met their goals, but Lilly only plans to submit a BLA in Q1 2027. It is investigational and not FDA-approved.

Educational content, not medical advice. This page explains a regulatory process; it does not forecast an availability date for any medicine, and it is not a route to obtaining anything described here.

Updated October 2026: re-checked 26 October 2026. Adds retatrutide as a worked example of every stage before "filed": TRIUMPH-2 and TRIUMPH-3 met their primary endpoints against placebo in July 2026, Lilly is finishing its manufacturing package, and the BLA is planned for Q1 2027 but not submitted. CagriSema and compounding status dates moved to 26 October 2026. Replaces a supply-verification CTA with a bloodwork-first recommendation.

---

If you follow a specific compound through the news, you will meet a series of headlines that all sound like arrival. A company "files." An agency "accepts." A committee "recommends." Eventually something is "approved," and later still it is "launched." Each of those is a real event with a real date, and the gaps between them are measured in quarters and years rather than weeks.

This matters most to the reader who is waiting. Reading a filing announcement as an availability announcement produces a specific and avoidable disappointment - and, more consequentially, it is the misunderstanding that the grey market is built to exploit. "It's basically approved" is a sales position, not a status.

Four things a headline can mean, and only one of them is "you can get it"

A fifth word appears in peptide coverage specifically and belongs to an entirely different system: compounding. It is addressed further down, because conflating it with drug approval is the single most common error in this space.

Filed: what a submission is and what it is not

A submission is a company telling a regulator: here is our complete evidence package, please assess it. In the United States, small-molecule medicines are submitted as a New Drug Application (NDA) and biologic medicines - including peptide products above a certain size - as a Biologics License Application (BLA). The distinction is procedural rather than a quality ranking, but it is worth noticing, because coverage routinely uses "NDA" as a generic term for any filing and the two pathways are not interchangeable.

What a filing establishes is that a company believes its evidence is sufficient and is willing to be judged on it. What it does not establish is that the regulator agrees. Filings can be refused at acceptance, can attract requests for further information, and can end in a decision that is not an approval. A stated intention to file is a further step back again - it is a plan, announced by a company, about something it has not yet done.

Under review: what the agency is doing, and how long it takes

Once a submission is accepted, the regulator assesses the evidence: whether the trials were adequate, whether the effect is real and clinically meaningful, whether the safety profile is acceptable for the proposed use, whether the manufacturing is controlled and reproducible. That last element - chemistry, manufacturing and controls - is unglamorous and frequently the rate-limiting step.

Review periods run to a defined target date, and a company will often signal roughly when it expects a decision. Two cautions apply. First, a company's stated expectation is not the agency's commitment; corporate guidance describes a plan, and plans move. Second, review can be extended, and an extension is routine rather than ominous.

An advisory committee may be convened during review. Its recommendation is non-binding - the agency is not obliged to follow it, and on occasion has not. A committee vote is emphatically not an approval, a point the library treats in detail in what the July 2026 peptide vote actually decided. Some medicines also travel a faster route, explained in what accelerated approval means; a faster route is still a route, and it still ends in a decision rather than skipping one.

A decision is not a launch

Approval authorises a medicine for specific uses in specific populations. Several things then remain between that authorisation and a person obtaining it: manufacturing at commercial scale, distribution, pricing and reimbursement negotiations, and prescriber familiarity. Launch timing after approval varies considerably.

And for readers outside the United States, the most important gap of all: a US approval is a US approval. Every country runs its own registration process, and a medicine approved in one market may be under review, unregistered, or simply not submitted in another. A US headline tells you almost nothing about availability in Kuala Lumpur, Jakarta or Bangkok. That specific gap, for the oral GLP-1 medicines, is mapped in oral GLP-1 pills in Southeast Asia.

Worked examples on the public record

Two current examples show the sequence at different points, and neither is a prediction.

CagriSema. Novo Nordisk submitted a New Drug Application to the FDA in December 2025, on the basis of the REDEFINE 1 and REDEFINE 2 trials. As of 26 October 2026 it remains under review and is not approved, and no agency decision date has been made public. Novo's own Form 6-K FY2026 carries the US decision as a stated Q4 2026 regulatory milestone - a company expectation, not a published agency date. Note what nine months of review looks like from the outside: a filing headline in December, then very little, then eventually a decision. Where it stands in full: CagriSema.

Retatrutide. This is the clearest live example of the gap between "the results are in" and "it has been filed". On 23 July 2026 Lilly announced that two more Phase 3 trials, TRIUMPH-2 (adults with type 2 diabetes) and TRIUMPH-3 (adults with established heart disease), had met their primary endpoints against placebo, and it now describes five positive Phase 3 studies behind the programme. It has said it is completing the manufacturing package (the chemistry, manufacturing and controls dossier) required to submit a Biologics License Application in Q1 2027. Read that carefully: as of 26 October 2026 the filing has not happened. In the table above, retatrutide is still in the first row. Retatrutide is investigational and not FDA-approved. A stated plan to file in early 2027 opens a review that will itself take many months, before any of the launch steps above begin. Anything currently sold as "retatrutide" outside a trial is not an approved medicine. The full picture: retatrutide, and the narrow physician-initiated route that does exist for a very small group of critically ill patients is described in retatrutide expanded access.

The wider pipeline, with the same caveats applied throughout, is mapped in the 2026–2027 weight-loss drug pipeline.

Why the compounding track is a different system with different words

Peptide coverage introduces a parallel vocabulary that does not belong to the approval process at all. Compounding is the preparation of a medicine by a pharmacy for an individual patient, governed by its own framework with its own categories, committees and lists.

The words are similar enough to be treacherous. A substance can be removed from a restricted category, recommended by a compounding advisory committee, or eventually listed as permitted for compounding - and none of those is FDA approval, none of them means the substance has been through the trials-to-approval sequence described above, and a recommendation does not put anything on a list. As of 26 October 2026 the peptides recommended in July have no final rule, and an interim policy sent to the White House for review in October has not been issued. How that system works is set out in how 503A compounding works, and the current status in the 2026 FDA peptide reclassification.

If a seller cites a committee vote as evidence that something is now legitimate, they are borrowing the authority of one system for a product that sits in another.

What to do with a headline about a compound you are following

Three questions resolve most of them. Which event is this? - filing, acceptance, committee, decision, or launch. Whose statement is it? - a company's plan, or a regulator's action. Which country? - and if it is not yours, the headline is context rather than news about your access.

None of that requires expertise; it requires reading the verb. And the practical implication is usually the same: a medicine that is not approved and not available is not a plan you can act on today, whatever the pipeline looks like. Where that leaves you is a conversation with your own doctor about the options that exist now.

Where to start. Whatever you are waiting on, the first useful step does not depend on a regulator: we recommend starting with baseline bloodwork, so that when an option does become available to you, you and your doctor already have your numbers.

Frequently asked questions

How long after an FDA submission is a drug available? There is no fixed interval, and the honest answer is that it varies. A submission opens a review measured in months, which can be extended; approval is then followed by manufacturing, distribution and pricing steps before a medicine reaches patients - and, outside the United States, by a separate registration process in each country. A filing headline is the start of a process, not a countdown.

What does "NDA filed" mean for patients? That a company has submitted its evidence package and the regulator has not yet decided. It is not an approval, it carries no guarantee of one, and the medicine is not available. A BLA is the equivalent filing for biologic medicines, including many peptide products.

When will retatrutide be available? No date can be given, and treat any source offering one with suspicion. Retatrutide is investigational and not FDA-approved. Its main Phase 3 trials have reported, and Lilly has said it plans to submit a BLA in Q1 2027 - a plan to file, not a filing (none had been made as of 26 October 2026), and not an approval. A review would follow that submission, and availability in any particular country would follow that.

Is a committee recommendation the same as approval? No. Advisory committee recommendations are non-binding, and in the case of the July 2026 peptide vote the committee recommended substances that the agency's own scientists had recommended against. For compounding specifically, a recommendation does not place a substance on the permitted list - that requires further sign-off and formal rulemaking, and as of 26 October 2026 no final rule exists.

Related reading

• What accelerated approval means · How 503A compounding works · The 2026–2027 weight-loss drug pipeline · Retatrutide expanded access · Where CagriSema stands · Research on what, in whom, measured how · When will CagriSema be approved?
• Part of The Beginner's Guide to Peptides

---

Educational content, not medical advice. Regulatory timelines change and the status of any medicine named here should be re-verified at the date of reading. Retatrutide and CagriSema are investigational and not FDA-approved. This page explains a process; it does not forecast availability and is not a route to obtaining an unapproved medicine. Claims for the Malaysian market are subject to MAB requirements.

References

• CagriSema: NDA submitted to FDA December 2025 on REDEFINE 1 and REDEFINE 2; under review and not approved as of 26 October 2026; US decision carried as a Q4 2026 regulatory milestone in Novo Nordisk Form 6-K FY2026. (PharmExec; Novo Nordisk; SEC filing.)
• Retatrutide: five positive Phase 3 studies; Lilly completing the chemistry, manufacturing and controls package for a BLA submission stated for Q1 2027; investigational and not FDA-approved. (BioPharma Dive; PharmExec; Lilly.)
• Eli Lilly investor release, 23 July 2026, "Lilly's triple agonist retatrutide successful in two additional Phase 3 obesity trials": TRIUMPH-2 and TRIUMPH-3 met their primary endpoints versus placebo at 80 weeks; US BLA submission planned Q1 2027. (investor.lilly.com)
• NDA and BLA as distinct submission pathways for small-molecule and biologic products.
• Advisory committee recommendations are non-binding; July 2026 PCAC recommended six peptides over an FDA staff recommendation against all seven; no final rule as of 26 October 2026; interim peptide compounding policy submitted to OMB for review in October 2026, not issued. (AJMC; NCPA; RAPS; McDermott; Holland & Knight, October 2026.)